Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion
NEW BRUNSWICK, N.J. – Johnson & Johnson announced that it has entered into a definitive agreement to acquire Momenta Pharmaceuticals (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. The deal provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson
